{"doi":"10.1016/j.canlet.2013.10.014","title":"T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant","abstract":null,"journal":"Cancer Letters","year":2014,"id":634170,"datarank":0.5050943744979712,"base_score":3.367295829986474,"endowment":3.367295829986474,"self_citation_contribution":0.5050943744979712,"citation_network_contribution":0.0,"self_endowment_contribution":0.5050943744979712,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":28,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1644623,"name":"Susanne K. Hansen","orcid":null,"position":1,"is_corresponding":false},{"id":1644624,"name":"Sarah L. Larsen","orcid":null,"position":2,"is_corresponding":false},{"id":1644625,"name":"Birgit E. Reiter","orcid":null,"position":3,"is_corresponding":false},{"id":1644626,"name":"Boe S. Sørensen","orcid":null,"position":4,"is_corresponding":false},{"id":1644627,"name":"Anne E. Lykkesfeldt","orcid":null,"position":5,"is_corresponding":false},{"id":1644622,"name":"Tove Kirkegaard","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant","abstract":"In this study, T47D cell lines resistant to the antiestrogen fulvestrant were established and analyzed to explore, whether a switch to HER signaling, as seen in fulvestrant resistant MCF-7 cell lines, is a general resistance mechanism. We find that parental T47D cells depend on ER and HER signaling for growth. Fulvestrant resistant T47D cells have lost ER expression and, although HER2 was over expressed, growth was only partially driven by HER receptors. Instead c-Src was important for resistant growth. Thus, the T47D and MCF-7 model system unravel different resistance mechanisms which may be important for fulvestrant resistant breast cancer patients.","is_dataset_classified":null,"base_score":3.367295829986474,"endowment":3.367295829986474,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"24513268","pmcid":null,"openalex_id":"https://openalex.org/W2116248166","authors":[],"funders":[],"total_grants":0,"fwci":1.7348,"citation_percentile":0.84731058,"influential_citations":0,"citation_trend":[{"year":2014,"count":1},{"year":2015,"count":7},{"year":2016,"count":4},{"year":2017,"count":3},{"year":2018,"count":1},{"year":2020,"count":1},{"year":2021,"count":4},{"year":2022,"count":2},{"year":2023,"count":1},{"year":2024,"count":2},{"year":2025,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S030438351300743X?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S030438351300743X?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.canlet.2013.10.014","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/24513268","host_type":"repository"},{"url":"https://pure.au.dk/portal/en/publications/64a8f434-d304-4ec7-8b3c-74bb6ad16701","host_type":""}],"fields_of_study":["HER2/EGFR in Cancer Research","Monoclonal and Polyclonal Antibodies Research","Estrogen and related hormone effects"],"mesh_terms":["Fulvestrant","CSK Tyrosine-Protein Kinase","Breast Neoplasms","Estradiol","Estrogen Antagonists","Humans","Receptors, Estrogen","Blotting, Western","Signal Transduction","Receptor, ErbB-2","Erb-b2 Receptor Tyrosine Kinases","Drug Resistance, Neoplasm","src-Family Kinases","Reverse Transcriptase Polymerase Chain Reaction","RNA, Small Interfering","Cell Line, Tumor","Immunoprecipitation","Real-Time Polymerase Chain Reaction"],"keywords":["Fulvestrant","Antiestrogen","Cancer research","ErbB","Estrogen receptor","Tamoxifen","Proto-oncogene tyrosine-protein kinase Src","Cancer","Signal transduction","Biology","Breast cancer","Cell biology","Genetics"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T13:16:31.107450Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}